Abstract
It is possible to decrease the rate of progression of coronary artery disease in diabetic patients by controlling all risk factors including hyperglycemia and by the prescription of statin and aspirin in high risk patients. After a coronary event, the management of the patient must be as optimal as possible in terms of pharmacological treatment and revascularization. "Ever more" is the key line in these patients.
MeSH terms
-
Adrenergic beta-Antagonists
-
Coronary Artery Disease / etiology
-
Coronary Artery Disease / therapy*
-
Diabetes Mellitus, Type 2 / complications*
-
Diabetes Mellitus, Type 2 / therapy
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypertension / prevention & control
-
Hypoglycemic Agents / therapeutic use
-
Platelet Aggregation Inhibitors
Substances
-
Adrenergic beta-Antagonists
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypoglycemic Agents
-
Platelet Aggregation Inhibitors